AR091687A1 - Formas solidas de inhibidores de fosfodiesterasa tipo 5 - Google Patents
Formas solidas de inhibidores de fosfodiesterasa tipo 5Info
- Publication number
- AR091687A1 AR091687A1 ARP130102407A AR091687A1 AR 091687 A1 AR091687 A1 AR 091687A1 AR P130102407 A ARP130102407 A AR P130102407A AR 091687 A1 AR091687 A1 AR 091687A1
- Authority
- AR
- Argentina
- Prior art keywords
- type
- solid forms
- phosphodiesterase inhibitors
- polymorphs
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cocristales complejos, solvatos y polimorfos de los mismos. Dichas sustancias se pueden emplear para preparar una composición farmacéutica que contiene al mismo como ingrediente activo útil. Dichos compuestos pueden presentar una estabilidad de almacenamiento constante. Reivindicación 1: Un cristal formado por un inhibidor de la fosfodiesterasa tipo 5 -tadalafil- de fórmula T y un co-formador Y, en donde Y es un grupo formador de puentes de hidrógeno seleccionado de derivados de ácidos hidroxicarboxilicos alifáticos y de ácidos hidroxicarboxílicos aromáticos; así como los solvatos, hidratos y polimorfos de T:Y.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012007915A MX357741B (es) | 2012-07-06 | 2012-07-06 | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091687A1 true AR091687A1 (es) | 2015-02-18 |
Family
ID=49881432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102407 AR091687A1 (es) | 2012-07-06 | 2013-07-05 | Formas solidas de inhibidores de fosfodiesterasa tipo 5 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9278970B2 (es) |
KR (1) | KR20150027797A (es) |
AR (1) | AR091687A1 (es) |
BR (1) | BR112015000168B1 (es) |
CA (1) | CA2878360C (es) |
ES (1) | ES2530423B1 (es) |
MX (1) | MX357741B (es) |
RU (1) | RU2634713C2 (es) |
WO (1) | WO2014006604A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
EP3871515A1 (en) * | 2014-05-27 | 2021-09-01 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
CN105481860B (zh) * | 2015-12-31 | 2018-03-02 | 山西普德药业有限公司 | 一种他达拉非i型晶体的精制工艺 |
CN109796461B (zh) * | 2018-12-30 | 2020-09-25 | 江苏科本药业有限公司 | 一种他达拉非杂质i的制备工艺 |
CN111718344A (zh) * | 2019-03-22 | 2020-09-29 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种他达拉非的精制方法 |
KR20220011671A (ko) * | 2019-05-23 | 2022-01-28 | 가켄 세이야쿠 가부시키가이샤 | 소프피로늄 브롬화물 결정체 및 그의 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
KR20070072891A (ko) * | 2004-11-02 | 2007-07-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타달라필 결정형 및 이의 제조 방법 |
EP2400848A4 (en) * | 2009-02-26 | 2012-07-25 | Thar Pharmaceuticals Inc | CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS |
MX357741B (es) * | 2012-07-06 | 2018-07-23 | Laboratorios Senosiain S A De C V Star | Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5. |
-
2012
- 2012-07-06 MX MX2012007915A patent/MX357741B/es active IP Right Grant
-
2013
- 2013-07-05 AR ARP130102407 patent/AR091687A1/es not_active Application Discontinuation
- 2013-07-06 WO PCT/IB2013/055530 patent/WO2014006604A1/es active Application Filing
- 2013-07-06 RU RU2015103834A patent/RU2634713C2/ru not_active IP Right Cessation
- 2013-07-06 US US14/412,272 patent/US9278970B2/en not_active Expired - Fee Related
- 2013-07-06 BR BR112015000168-8A patent/BR112015000168B1/pt not_active IP Right Cessation
- 2013-07-06 CA CA2878360A patent/CA2878360C/en active Active
- 2013-07-06 KR KR1020157000778A patent/KR20150027797A/ko not_active Application Discontinuation
- 2013-07-06 ES ES201590001A patent/ES2530423B1/es not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
MX357741B (es) | 2018-07-23 |
CA2878360C (en) | 2020-08-18 |
ES2530423R1 (es) | 2015-04-06 |
US20150152107A1 (en) | 2015-06-04 |
RU2015103834A (ru) | 2016-08-27 |
WO2014006604A1 (es) | 2014-01-09 |
BR112015000168A2 (pt) | 2017-06-27 |
ES2530423A2 (es) | 2015-03-02 |
KR20150027797A (ko) | 2015-03-12 |
ES2530423B1 (es) | 2016-01-21 |
US9278970B2 (en) | 2016-03-08 |
MX2012007915A (es) | 2014-01-21 |
RU2634713C2 (ru) | 2017-11-03 |
CA2878360A1 (en) | 2014-01-09 |
BR112015000168B1 (pt) | 2022-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091687A1 (es) | Formas solidas de inhibidores de fosfodiesterasa tipo 5 | |
NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
CR20150629A (es) | Compuestos químicos | |
ECSP12012334A (es) | Morfolinopirimidinas y su uso en terapia | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
CU20140109A7 (es) | Compuestos heterocíclicos | |
CR20150045A (es) | Inhibidores de hepatitis c | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
CL2012003546A1 (es) | Compuestos especifico acido 2-(3-(4-cianonaftalen-1-il)piridin-4-iltio)-2-metilprpanoico, en su uso fromula markush; composicion y combinacion farmaceutica que lo comprende; y uso del compuesto y de la combinacion farmaceutica en la preparacion de medicamentos para tratar enfermedades originadas por altos niveles de acido urico. | |
BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
BR112018012106A2 (pt) | forma cristalina de inibidor de btk quinase e método de preparação da mesma | |
NI201500096A (es) | Compuesto químicos | |
CU20110145A7 (es) | Derivados de sulfonamida | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
SV2012004235A (es) | Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ES2678086T3 (es) | Compuestos de diona cíclicos (alquil-fenil)-sustituidos activos como herbicidas y derivados de los mismos | |
CU24330B1 (es) | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) | |
CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |